Abstract: The present disclosure relates to methods and compositions comprising cannabidiol (CBD) and a volatile anaesthetic, particularly isoflurane, useful for treating or preventing traumatic brain injury (TBI).

Abstract: Compositions including ?-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising an oil-in-water emulsion having a dispersed oil phase and a continuous water phase, wherein the dispersed oil phase comprises cannabidiol (CBD) or a pharmaceutically acceptable salt or functional derivative thereof, wherein the composition is formulated for administration by inhalation. The composition is intended for use in the treatment of traumatic brain injury (TBI).

Abstract: The present disclosure relates generally to compositions comprising a synergistic combination of cannabidiol (CBD) or a pharmaceutically acceptable salt or derivative thereof and hydroxychloroquine or a pharmaceutically acceptable salt thereof, which beneficially enables simultaneous administration of the two active pharmaceutical ingredients (APIs) in a single dosage form. In an embodiment, the present disclosure also relates to methods and uses of the composition for the treatment of an inflammatory condition.

Abstract: Compositions including ?-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

Abstract: Compositions including cannabidiol (CBD) and hydroxychloroquine (HCQ) or pharmaceutically acceptable salts thereof, and their use in methods for the treatment of an inflammatory condition, or for modulating an immune response. The methods and compositions are useful for the treatment or prevention of an inflammatory condition, including but not limited to, inflammatory bowel disease, arthritis, and inflammatory respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, cystic fibrosis (CF) and acute respiratory distress syndrome (ARDS).

Abstract: The present disclosure relates to methods and compositions comprising cannabidiol (CBD) and a volatile anaesthetic, particularly isoflurane, useful for treating or preventing traumatic brain injury (TBI).